Therapeutic targeting of IL17A and IL21 has been evaluated in clinical trials for a variety of inflammatory and autoimmune indications, and anti-IL17A monoclonal antibodies were recently approved for psoriasis. This evidence concerns the gene IL17A and psoriasis.